Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

NCT05635071 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Uterine Adhesions

Interventions

DRUG: Nintedanib 100 MG [Ofev]
DRUG: Nintedanib 150 MG [Ofev]

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University